Wesley JvR/peopleimages.com/stock.adobe.com

Mashura, an inventory intelligence platform in healthcare, shared earlier this week that it has entered a $300 million strategic partnership with a newly formed financing vehicle sponsored by, Warburg Pincus, a pioneer of private equity growth investing that was founded in 1966 and has more than $86 billion in assets under management and over 230 companies in their active portfolio.

"One of my core focuses is to foster a culture at Mashura that emphasizes serving one another, developing innovative solutions, and creating programs that enhance healthcare for both people and their pets. Through our best-in-class solutions, we help healthcare companies maximize profitability, control inventory, and optimize workflow efficiencies, thereby increasing safety and mitigating risk," said Anton Visser, CEO, Mashura, in an organizational release.

"This partnership unlocks an exciting new opportunity for Mashura, allowing us to innovate, expand and drive continued success. The support from Warburg Pincus is invaluable and we look forward to leveraging their decades-long experience in healthcare and financing strategies," he continued.

According to the release, Mashura is a global leader in inventory intelligence solutions and provides smart cabinet technology to both veterinary and dental clinics, resulting in hard dollar cost savings through streamlined operations, improved inventory management. Mashura also ensures seamless compliances with state and Drug Enforcement Agency regulatory audits.

Mashura operates through 2 specialized brands, CUBEX, which serves the veterinary industry, and Zimbis, which serves the dental industry. The company provides solutions that are tailored to the unique to meet each market, such as its software platform that offers real-time reporting and institutive analytics, empowering its customers to prioritize operational demands and optimize inventory supply.

"Mashura is a valued part of the vet and dental markets with their innovative storage cabinets, helping clients with increased billing capture, reduced inventory, consolidated analytics, automated suggested ordering and regulatory audits – all important services for healthcare providers," said José Arredondo, principal, Warburg Pincus.

With installations in over 16 countries, Mashura’s solutions have potential to transform the way health care providers manage inventory as well as improve overall patient outcomes. Mashura will also focus on expanding its customer base across the world, increase integration partnerships, and innovate key solutions.

Warburg Pincus Capital Soultions Founder Fund provided the equity for the transaction and officially closed in September 2024, with more than $4 billion in commitments. Mitsubishi Corporation remains a strategic partner to Mashura.

"We are excited to partner with Anton and the CUBEX and Zimbis teams on this next phase of growth, expanding the reach and services for the company to benefit customers as the demand for automation solutions continues to accelerate," concluded Jordan Jones, principal, Warburg Pincus.

Mashura Announces $300M Strategic Partnership with Warburg Pincus. News release, Mashura. January 7, 2025. Accessed January 8, 2025. https://www.prnewswire.com/news-releases/mashura-announces-300m-strategic-partnership-with-warburg-pincus-302343029.html

Articles

The $300 million partnership will incite expand client reach, growth, and innovation within veterinary and dental markets

Mashura announces strategic partnership with Warburg Pincus 

Karen Roach, RVT, VTS (ECC), discusses caring for pets and livestock during a wildfire or other disaster event.

Emergency evacuation with pets

Preparing pets and livestock for evacuation during a wildfire, hurricane or other disaster event can help transport go smoother. In an interview with 

, Karen Roach, RVT, VTS (ECC), a team trainer at Mount Laurel Animal Hospital in New Jersey with experience treating animals injured in disaster situations, discusses what veterinary teams can communicate to their clients about caring for pets, especially felines. Roach also provides advice for managing large animals, including livestock, before and during a disaster event.

The following is a transcript of the video:

For any type of disaster—weatherwise, earthquakes, anything like that—it is good to be prepared ahead of time. Have a ‘go bag’ for your pet, which is going to include any medications they're on, some food, some water, [and] identification. The other thing is to have your pet [familiar with] being scooped up and shoved in the car really fast. If you have to evacuate because there's a fire coming, with cats, especially, that can be hard to do. So, having their crate or their carrier of some kind out fairly frequently, so they get used to it. Put bedding in there, put treats in there. So, [that] they know it's kind of a safe space and if you have to put them in there, it's not going to be a big shock.

If you have animals that you can't just throw in your car, you might need to just let them loose. Let them get out of the way on their own and find them later. I know we don't often microchip our horses and goats, but that might not be a bad idea—to have some kind of [identification] on if you have those kind of pets or livestock.

[An evacuation] can be really scary. So, being prepared ahead of time is definitely going to help getting your pets into the car.

Videos

Karen Roach, RVT, VTS (ECC), discusses caring for pets and livestock during a wildfire or other disaster event

Preparing animals for emergency evacuation

In a recent “Dear Veterinarian” letter, the FDA alerted veterinarians of adverse events in dogs treated with bedinvetmab injection (Librela; Zoetis). The monoclonal antibody drug is used to manage pain associated with osteoarthritis in dogs. It is dosed based on the dog’s weight and is intended for subcutaneous injection once a month.

In its letter, the federal agency listed neurologic signs like ataxia, seizures, paresis, recumbency, urinary incontinence, polyuria, and polydipsia as adverse events identified and analyzed in an FDA evaluation of adverse events.

Excessive thirst, urination, and even death, including euthanasia, were also documented as outcomes.

In two-thirds of the reported events, clinical signs occurred within the first week after administration, while 30% occurred within the first day.

 In 70% of the reported cases, signs were noted following the first dose of the drug. Approximately 30% of the reported cases indicated that no other products were used alongside the drug.

Librela received FDA approval on May 5, 2023 and was introduced to the marketplace later that year.

The federal agency reviewed the available studies and other data on the drug prior to its approval, and concluded that Librela was safe and effective for its intended use.

 Since the drug’s release, however, veterinarians and pet owners have reported adverse events, leading the FDA to conduct the evaluation, according to the American Veterinary Medical Association.

published an article with pet owner claims of their pets experiencing adverse reactions to bedinvetmab injection and frunevetmab injection (Solensia; Zoetis) instead of the expected improvement in their conditions. One case included a 12-year-old dog that experienced decreased mobility, appetite loss, lethargy, and kidney failure before being euthanized 2 months after receiving Librela for hip stiffness.

 Similar cases involving another dog and a 16-year-old cat treated with bedinvetmab or frunevetmab were also reported, sparking attention on social media.

“If a dog under your care experiences an adverse event while receiving Librela, the FDA encourages you to report it to Zoetis, the drug sponsor, at 1-888‑963-8471. Drug sponsors are required to submit reports of adverse drug events to FDA. If you prefer to report directly to FDA, please see 

spoke to Zoetis last April about reports of adverse effects in a number of patients taking Librela or Solensia (frunevetmab injection). “There are rare adverse events, like any other medication,” Richard Goldstein, DVM, DACVIM, DECVIM-CA, global chief medical officer for Zoetis, told 

 “We are very confident in the safety and efficacy of Librela and Solensia. We are very confident with the fact that [Librela] is efficacious, that it's helping thousands of dogs worldwide. But [we are] also aware that a small percentage of cases, just like any other drug, have potential side effects.”

A clinical trial involving 287 dogs found that monthly bedinvetmab injections reduced osteoarthritis pain compared to a placebo. Participants receiving bedinvetmab injection also experienced improved mobility and overall quality of life as a result of the pain relief, according to a 

Following the FDA’s “Dear Veterinarian” letter, Zoetis published a statement reaffirming its confidence in the product’s safety and performance and its alignment with the FDA’s monitoring of the drug’s safety and efficacy. “At Zoetis, we work closely with the FDA and other global regulatory agencies to provide context to reported events,” wrote Zoetis in its statement.

 “As part of this process, we are discussing label updates with FDA which we expect will reflect post-approval adverse event reporting and be consistent with those included on labels in other markets.”

Dear Veterinarian Letter notifying veterinarians about adverse events reported in dogs treated with Librela (bedinvetmab injection). News release. US Food and Drug Administration. Accessed January 8, 2025. 

https://www.fda.gov/animal-veterinary/product-safety-information/dear-veterinarian-letter-notifying-veterinarians-about-adverse-events-reported-dogs-treated-librela

FDA: Adverse events in dogs reported with monoclonal antibody drug. American Veterinary Medical Association. January 7, 2024. Accessed January 8, 2025. 

https://www.avma.org/news/fda-adverse-events-dogs-reported-monoclonal-antibody-drug?utm_source=delivra&utm_medium=email&utm_campaign=todays-headlines-news

Coppock K, McCafferty C, Yankowicz S. Animal health company assures veterinarians that OA drugs are safe. 

. April 16, 2024. Accessed January 8, 2025. 

https://www.dvm360.com/view/animal-health-company-assures-veterinarians-that-oa-drugs-are-safe

Corral MJ, Moyaert H, Fernandes T, et al. A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis. 

. 2021;48(6):943-955. doi:10.1016/j.vaa.2021.08.001

Zoetis statement on the safety of Librela. Zoetis. December 18, 2024. Accessed January 9, 2025. 

https://news.zoetis.com/press-releases/press-release-details/2024/Zoetis-Statement-on-the-Safety-of-Librela/default.aspx

Neurologic signs were reported with bedinvetmab injection use in dogs

FDA notifies veterinarians of adverse events linked to canine osteoarthritis treatment

Joe Jesse Owens III, DVM, inventor and CEO of Enjoy-A-Bowl and executive producer of But I Love My Pet, joined this week's episode of The Vet Blast Podcast presented by dvm360 with our host Adam Christman, DVM, MBA. The duo sat down to discuss the importance of clear communication, setting professional boundaries, and prioritizing self-care to help veterinary teams ensure they can balance client expectations and animal welfare to make sure pets are getting the care they need and patients gain a better understanding of the issues surrounding their pet. 

So talking about the art of negotiating for a life. You know your perspective. You have have been through so many different aspects already in your career. So what inspired you to view your role as a veterinarian through the lens of negotiation and decision making.

I mean, at the end of the day, this pet can't talk. You know, animal science degree teaches you what's normal in a pet. Veterinary medicine teaches you all the abnormals and what's wrong. And then you have to find that balance for a person who has no knowledge in what this animal is doing, and a lot of times they normalize bad things like limping. He's always limped, not normal. We normalize it. So how do we negotiate the quality of life to get you to realize that this pets in pain and uncomfortable at best, because it's not your pain, and it's hard to relate to that from the pets perspective, when I'm trying to help you, and I know you're here for vaccines, but he don't want vaccines right now. He want this knee at least addressed in some pain management on board. 

So how do I get you to relate to that in a way that makes sense to you, so that we can relate to the dog, and then we get compliance, and then you see the results, because you agreed with me, and I always say, but what if I'm right? Even if we go back and forth, what if I'm if I'm right, I could be wrong, but what if I'm right? Yes, and he can't talk, you know?

Podcasts

Adam Christman, DVM, MBA, and Joe Jesse Owens III, DVM, discuss the importance of clear communication and setting boundaries to balance client needs and patient welfare. 

The art of negotiating for a life: A veterinarian's perspective

Product360 with Ryan Gallagher, CEO of Scribenote

Scribenote leverages AI to save veterinarians time on note-taking

 Hey everyone, I'm Dr Adam Christman, Chief Veterinary Officer here at dvm360. Welcome to Product360! We're going to be chatting with our friends at Scribenote. We have Ryan Gallagher, CEO of Scribenote, chatting with us about making our lives easier and helping with our SOAP notes and workflow utilization. I'm really curious to learn more about this because we hear a lot about AI technology. I want to back up a little bit—tell us how Scribenote came to fruition.

Scribenote came to fruition in the earlier days of AI. Back in 2019, I was a university student and I noticed my older sister, Dr Katie Gallagher, who is a practicing veterinarian, coming home late all the time—an hour and a half, two hours late, always missing family dinner.

I was an engineering student, so I thought maybe there was something I could do to help. I followed her into the clinic as a fly on the wall. What I saw that day was the thing keeping her late was her medical records. These were often near duplications of what she’d been talking about all day long: Why is Fluffy here? What’s wrong with Fluffy? What are we going to do about it?

That forms the basis of the medical record. I thought if we could record the appointment using software, then process it into a note for her, maybe we could get her home on time. I told her at the end of that day, December 29, 2019, "Give me a decade, and we’ll figure this out." Well, it wasn’t a decade; we figured it out in about three and a half years. Since then, we’ve helped thousands of veterinarians, completed over two million medical records, and I’d love to show you how it feels.

That’s fantastic! Congratulations on doing that.

So, we obviously have a fake dog here, and we’re going to do a simulation. What should we do first? Should we demonstrate the software or start with a physical exam?

Let’s do a physical exam. I’ve got Scribenote pulled up on the computer here and also on my phone. Scribenote is cloud-based, so whatever you do on your phone syncs automatically with your computer. For demonstration purposes, you’d walk into the exam room, ask your client for consent to record, click a button, and focus on your exam as usual.

We’re going to say this is Capone, and you’re the owner, Ryan. I understand Capone came in for shaking his ears, correct?

 Yeah, he’s been itching and shaking his ears for the past two and a half weeks. He cries a little when he does it, and I’m getting worried.

 Okay, let’s take a look. His gum color looks nice, pink, and moist. Capillary refill time is less than two seconds. There’s a bit of dental disease—grade one out of four. His eyes look good. For the purpose of this conversation, let’s jump to the ears. The right ear (AD) has mild ceruminous discharge, and the left ear (AS) looks like it has some brown ceruminous discharge as well. I’d want to get an ear cytology to check for bacteria and/or yeast. I’ll come back with the treatment plan so you can go home with medication, and I want to show you how to clean his ears.

 That sounds great. I’m just worried because I need to take my kid to karate and there is a lot of karate practice these days. Is this going to take a long time?

 No, it’s not going to take that long, Ryan. This will only take about five minutes or so to get those results back.

 Okay. The kids have been wild since going back to school, but I appreciate it. One of the most common questions we get is, "Your exam room conversation isn’t like the dictation we just did, right?" That was for the sake of time—exam room conversations are unstructured. They include talk about kids, vacations, and other unrelated topics. When we pull up this record, hopefully as part of a live demo, you won’t see any of that. You’ll just see the relevant information for the patient.

In fact, you can see right here on the screen that the note in our inbox has already been processed. It’s done. We have a medical record for Capone, who presented with ear itching and head shaking. Looking at the record, we can see it’s been going on for about two and a half weeks. The patient has been crying when shaking his head. No other concerns were mentioned.

I won’t go through the entire objective, but what we see here is that Scribenote has automatically extracted key clinical information and put it where it belongs in the objective. It also calls out items that weren’t mentioned. Now, some people say, “I don’t want ‘not mentioned’ showing up throughout my exams.” That’s where customizable defaults come in. For example, if you want a default body condition score to show 4 out of 9 when it isn’t discussed, we can set that up. We call this feature custom objective defaults. If you say something like, “Looks good,” or, “Sounds normal,” it will default to your predefined normal values.

 As we scroll through the rest of the exam, you’ll notice there’s no mention of karate, but we did pull out your assessment: bilateral otitis externa, mild dental disease graded 1 out of 4, and follow-up plans. This happens automatically. If you really want to test its capabilities, bring it into a 45-minute appointment where you discuss everything. You’ll still see only the relevant information surfaced at the end.

 I’m smiling because this probably just saved me at least 15 minutes on one case—writing up notes, doing the rule-outs, and putting the plan in place. Look how organized it is with bulleted points, as well. So, how do we export this? Is there a drag-and-drop feature?

 Yes, Scribenote makes it easy to export into your PIMS. While I don’t have a PIMS on this computer, the process is as simple as copy-paste. It takes about 10 seconds per record. What used to take 15 minutes now takes 1 minute to review and 10 seconds to transfer into your system.

How Scribenote uses AI note taking to save veterinarians valuable time.

Zomedica Corp. (Zomedica), a veterinary health company that offers point-of-care diagnostics and therapeutic products for companion and equine animals, shared today that it was entered into a license and supply agreement with Creslion, Inc. This entered agreement gives Zomedica the ability to market and sell Vetigel hemostatic gel producer line on an exclusive basis within the United States and non-exclusive basis outside of the US.

"This partnership with Zomedica is ideal for the future of Vetigel," said Joe Landolina, CEO of Cresilon, in the organizational release.

 "Zomedica's established reputation, robust field sales team, and commitment to veterinary excellence make them the perfect match for expanding the reach of this revolutionary product. Together, we look forward to making Vetigel an essential tool for veterinary practices worldwide."

According to the release, Vetigel, which made its debut to the market in 2021,

is a plant-based formula that is designed to stop bleeding rapidly when applied directly to the source. The product is made of 2 plant-based polysaccharides that can stop the bleeding immediately at the wound site without manual pressure, preparation, or special storage conditions.

 Vetigel also does not integrate with the robust fibrin patch, creating a mechanical barrier instantly.

The product stops the bleeding in seconds without becoming incorporated into the clot and was validated in clinical studies. The studies found Vetigel’s ability to save time during surgical procedures and significantly reduce blood loss. Some of the key applications include:

: Successfully managed bleeding in advanced and routine procedures.

: Providing efficacy in treating arterial and venous bleeds.

: Demonstrated to stop bleeding faster than competitive hemostatic agents.

: Effective in controlling bleeding throughout soft organ biopsies and excisions.

"We are excited to add Vetigel to Zomedica's portfolio of innovative veterinary products," said Kevin Klass, Senior Vice President of Sales at Zomedica. "Vetigel's ability to rapidly stop bleeding across a variety of procedures makes it an invaluable tool for veterinarians, enabling them to enhance patient outcomes while improving surgical efficiency. This partnership with Cresilon allows us to bring cutting-edge solutions to veterinary professionals in the US and beyond."

In 2023, Vetigel was used to help save the life of Benji, a Malteese Yorkie, who was brought into the Veterinary Emergency & Referral Group in Brooklyn, New York with a stab wound.

 Matthew Morgan, DVM, DACVS-SA, chief of surgery at VERG, accredited Benji surviving the ordeal to Vetigel.

“Benji came to us in rough shape with a large stab wound,” said Morgan.

 “Fortunately, we were able to use Vetigel to stop the traumatic bleeding and ultimately save Benji’s life.”

To learn more information about the Vetigel hemostatic gel, visit the Zomedica website.

Zomedica Announces License & Supply Agreement with Cresilon Inc. to Market and Sell Vetigel(R) Hemostatic Gel in the Animal Health Market. News release. Zomedica Corp. January 7, 2025. Accessed January 8, 2025.

Yankowicz S. VETIGEL comes to the veterinary market. dvm360. August 28, 2023. Accessed January 8, 2025. https://www.dvm360.com/view/vetigel-comes-to-the-veterinary-market

Cresilon announces distribution agreement for VETIGEL with Penn Veterinary Supply. News release. Cresilon, Inc. August 22, 2023. Accessed August 28, 2023. 

https://vetigel.com/blogs/news/cresilon-announces-distribution-agreement-for-vetigel-with-penn-veterinary-supply

Dvm360 staff. VERG veterinarians save stabbed Morkie. dvm360. March 1, 2023. Accessed January 8, 2025. https://www.dvm360.com/view/verg-veterinarians-save-stabbed-morkie

Emergency veterinarian hospital saves escaped Morkie stabbed in streets of New York. News release. The Veterinary Emergency & Referral Group. March 1, 2023. Accessed January 8, 2025.

The agreement allows Zomedica to market and sell Vetigel(R) Hemostatic Gel
